Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Prevent Blindness has designated November 18 to 24, 2024, as the 5th annual Thyroid Eye Disease (TED) Awareness Week. The ...

HelpMeSee has partnered with new initiatives to address the global cataract blindness crisis, focusing on empowering women in ...

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of ...

Pediatric cataract surgeries are more costly than adult procedures, with significant nonsurgical expenses like anesthesia and ...

In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has ...

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables ...

FDA clearance of HG202 marks a significant milestone for CRISPR/Cas13 RNA-editing in clinical applications for nAMD. The ...

Atsena Therapeutics and Nippon Shinyaku have formed an exclusive licensing agreement for ATSN-101, a gene therapy for Leber ...

Vevye will be included in key formularies of major plan sponsors, covering over 25 million Medicare Part D beneficiaries ...